Resveratrol supplementation reduces ACE2 expression in human adipose tissue

M. de Ligt, M.K.C. Hesselink, J. Jorgensen, N. Hoebers, E.E. Blaak, G.H. Goossens*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Angiotensin converting enzyme-2 (ACE2) is the cell-surface receptor enabling cellular entry of SARS-CoV-2. ACE2 is highly expressed in adipose tissue (AT), rendering AT a potential SARS-CoV-2 reservoir contributing to massive viral spread in COVID-19 patients with obesity. Although rodent and cell studies suggest that the polyphenol resveratrol alters ACE2, human studies are lacking. Here, we investigated the effects of 30-days resveratrol supplementation on RAS components in AT and skeletal muscle in men with obesity in a placebo-controlled cross-over study. Resveratrol markedly decreased ACE2 (similar to 40%) and leptin (similar to 30%), but did neither alter angiotensinogen, ACE and AT1R expression in AT nor skeletal muscle RAS components. These findings demonstrate that resveratrol supplementation reduces ACE2 in AT, which might dampen SARS-CoV-2 spread in COVID-19.
Original languageEnglish
Pages (from-to)408-411
Number of pages4
Issue number1
Publication statusPublished - 1 Jan 2021


  • Resveratrol
  • ACE2
  • leptin
  • SARS-CoV-2
  • Covid-19
  • renin-angiotensin-system

Cite this